Larimar Therapeutics
Price & Volume
Stats
See more52W Range | $1.61-$11.20 |
Market Cap | $151.7M |
Shares Short | 5M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.32 |
News
See moreYahoo Finance • last month
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Yahoo Finance • 2 months ago
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Yahoo Finance • 3 months ago
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Yahoo Finance • last year
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
About
CEO | Dr. Carole S. Ben-Maimon M.D. |
CFO | Mr. Michael Celano CPA |
Address | Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 65 |
